16634-88-1

Basic information

• Product Name: 5-BROMO-3-NITROSALICYLALDEHYDE 97
• Synonyms: 5-BROMO-3-NITROSALICYLALDEHYDE 97;5-Bromo-3-nitrosalycylaldehyde;2-Hydroxy-3-nitro-5-bromobenzaldehyde;benzaldehyde, 5-bromo-2-hydroxy-3-nitro-;3-Nitro-5-broMosalicylaldehyde;Salicylaldehyde, 5-bromo-3-nitro-
• CAS NO: 16634-88-1
• Molecular Formula: C₇H₄BrNO₄
• Molecular Weight: 246.01
• EINECS: 1533716-785-6
• Product Categories: Aldehydes;C7Organic Building Blocks;Carbonyl Compounds;Nitro Compounds;Nitrogen Compounds
• Mol File: 16634-88-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 125-127 °C
• Boiling Point: 265.8 °C at 760 mmHg
• Flash Point: 114.6 °C
• Appearance: /
• Density: 1.928 g/cm³
• Vapor Pressure: 0.00546mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 4.23±0.38(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 5-BROMO-3-NITROSALICYLALDEHYDE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-NITROSALICYLALDEHYDE 97(16634-88-1)
• EPA Substance Registry System: 5-BROMO-3-NITROSALICYLALDEHYDE 97(16634-88-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 16634-88-1(Hazardous Substances Data)

Usage

General Description

5-Bromo-3-nitrosalicylaldehyde, 97% is a chemical compound with a purity level of 97%, implying it's largely unadulterated with other substances. It's used in a variety of laboratory and industrial processes as a specialized reagent. 5-BROMO-3-NITROSALICYLALDEHYDE 97 is often used in organic synthesis, a chemistry sub-discipline involving the construction of organic compounds. The particular properties of 5-Bromo-3-nitrosalicylaldehyde, including its bromo and nitro components, make it a valuable ingredient in a variety of chemical reactions. It should be handled with care, as with any chemicals, due to potential safety risks and should be stored under specific conditions to ensure its stability and efficacy. Specific details of its use, storage, and safety can be found in its Material Safety Data Sheet.

InChI:InChI=1/C7H4BrNO4/c8-5-1-4(3-10)7(11)6(2-5)9(12)13/h1-3,11H

Upstream product

• 128872-69-5 {Cu(C₇H₃BrNO₄)2dpy2} 
• 5274-70-4 3-nitrosalicylic aldehyde 
• 90-02-8 salicylaldehyde 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 13034-70-3 6-bromo-1',3',3'-trimethyl-8-nitro-1',3'-dihydro-spiro[chromene-2,2'-indole] 
• 99833-63-3 C₁₉H₁₅BrN₂O₅ 
• 98592-10-0 5-bromo-2-hydroxy-3-nitro-cis-cinnamic acid 
• 681850-07-7 C₂₆H₁₉BrN₂O₄ 

Relevant articles and documents

Campestarenes: New building blocks with 5-fold symmetry

Campestarene is a planar, shape-persistent macrocycle with 5-fold symmetry. A range of derivatives bearing peripheral functional groups suitable for generating supramolecular interactions has been designed and synthesised for potential applications in creating 2D quasicrystal molecular assemblies. The new campestarene derivatives bear ester, carboxylic acid, methoxy, bromo, 4-pyridyl, 4-cyanophenyl and 4-phenyl carboxylic acid groups, including further derivatives of the latter two bearing alkyl chains on the phenyl groups to improve solubility. The campestarene derivatives were prepared by reductive condensation of phenol precursors bearing nitro and formyl groups using Na2S2O4. The target functional groups were installed either by pre-cyclisation derivatisation or by synthesis of methoxy-substituted campestarene and subsequent derivatisation. The cyclisation reaction is tolerant of the functional groups introduced. The ten new campestarene derivatives were characterised by NMR spectroscopy and MALDI-TOF MS, although the poor solubility of some examples precluded their detailed characterisation.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one

The present invention relates to an extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates